sanofi-aventis sales and marketing update

sanofi-aventis launched Oforta fludarabine in the U.S. as second-line therapy to treat B cell chronic lymphocytic leukemia (B CLL). The wholesale acquisition cost (WAC) of Oforta will be about $2,700 per month, with a 6-month cost of $16,200. sanofi-aventis acquired exclusive, U.S. rights to the oral purine nucleoside analog from Antisoma plc (LSE:ASM, London, U.K.) in 2009. Antisoma gained the product through its 2008 acquisition of Xanthus Pharmaceuticals Inc., which had U.S. rights to the drug from Bayer AG (Xetra:BAY, Leverkusen, Germany). ...